List of Contents

Tumor Necrosis Factor Inhibitor Drugs Market Size, Share, and Trends 2024 to 2033

Tumor Necrosis Factor Inhibitor Drugs Market (By Product: Humira, Enbrel, Remicade, Simponi, Cimzia; By Application: Autoimmune Disease, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others, By Sales Channel: Hospital pharmacies, Specialty pharmacies, Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 4224
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Tumor Necrosis Factor Inhibitor Drugs Market 

5.1. COVID-19 Landscape: Tumor Necrosis Factor Inhibitor Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Tumor Necrosis Factor Inhibitor Drugs Market, By Product

8.1. Tumor Necrosis Factor Inhibitor Drugs Market Revenue and Volume, by Product, 2024-2033

8.1.1 Humira

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Enbrel

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Remicade

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Simponi

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Cimzia

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Tumor Necrosis Factor Inhibitor Drugs Market, By Application

9.1. Tumor Necrosis Factor Inhibitor Drugs Market Revenue and Volume, by Application, 2024-2033

9.1.1. Autoimmune disease

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Psoriasis

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Psoriatic arthritis

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Crohn’s disease

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Ulcerative Colitis

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Ankylosing spondylitis

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. Juvenile idiopathic arthritis

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. Hidradenitis suppurativa

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. Others

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Tumor Necrosis Factor Inhibitor Drugs Market, By Sales Channel 

10.1. Tumor Necrosis Factor Inhibitor Drugs Market Revenue and Volume, by Sales Channel, 2024-2033

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Specialty Pharmacies

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Specialty Pharmacies

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Tumor Necrosis Factor Inhibitor Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)

Chapter 12. Company Profiles

12.1. UCB Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Pfizer Inc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson & Johnson

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Amgen Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Abbvie

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us